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Abstract
Background: SIRT3, a member of the sirtuin family of NAD+-dependent deacetylases, resides primarily in the
mitochondria and has been shown to deacetylate several metabolic and respiratory enzymes that regulate
important mitochondrial functions. Previous researches show an important role of SIRT3 in regulating the
production of reactive oxygen species (ROS), and highlight the ability of SIRT3 to protect cells from oxidative
damage. A key substance of renin-angiotensin-aldosterone system (RAAS), Angiotensin II (AngII) can induce cells
dysfunction by increasing the production of ROS. In this paper, we focus on the role of SIRT3 in AngII-induced
human umbilical vein endothelial cells (HUVECs) dysfunction.
Methods: To study the influence of AngII on SIRT3 expression, HUVECs were treated with AngII of 10−7, 10−6, 10−5 mol/L
for 24 h. SIRT3 expression was detected by wester-blotting analysis and RT-PCR. In addition, to research the role of SIRT3
in AngII-induced HUVECs,we used SIRT3 siRNA to knock down SIRT3 expression in HUVECs. Cells pretreated with negative
control siRNA or SIRT3 siRNA were exposed to AngII for 24 h, and endothelial nitric oxide synthase (eNOS) expression,
eNOS activity, total level of nitric oxide (NO) and ROS generation of each group were detected.
Results: Here we show that AngII treatment could increase generation of ROS, and decrease eNOS activity and total level of
NO, while upregulated eNOS expression as a compensatory mechanism. The stimulation of AngII upregulated the expression
of SIRT3 in HUVECs. SIRT3 siRNA worsen the AngII-induced effects above, besides, downregulated eNOS protein expression.
Conclusion: These data suggest that SIRT3 plays a role of protection in AngII-induced HUVECs dysfunction via regulation of
ROS generation.
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Background
As the inner layer of the blood vessel wall, the endothelium
plays the major role in the regulation of vascular homeosta-
sis and is the target for a variety of neurotransmitters,
hormones, or physiologic stimuli. Endothelial dysfunction,
mainly refer to an impairment of endothelium-dependent
vasorelaxation caused by a loss of nitric oxide (NO)
bioactivity in the vessel wall, is observed in the presence of
major cardiovascular risk factors, including atherosclerosis,
hypertension, and heart failure [1–3]. A large body of
evidence invariably demonstrates that the presence of
endothelial dysfunction is a hallmark of the hypertensive
patient [4]. Notably, endothelial dysfunction can occur at
an early stage of hypertension, and may make an important
contribution to the increase of blood pressure. On the
other hand, endothelial dysfunction is considered as a
consequence of hypertension, and, in these conditions
endothelial dysfunction may contribute to further increases
in peripheral vascular resistance and cardiovascular compli-
cations [5]. Reduced bioavailability of NO and abundant
formation of reactive oxygen species (ROS) within the
vascular wall are the key determinants in endothelial
dysfunction [6].
Angiotensin II (AngII), a key substance of renin-
angiotensin-aldosterone system (RAAS), can cause vaso-
constriction, sympathetic nervous stimulation, release of
aldosterone, and renal actions which contribute to control
the blood pressure [7]. AngII can induce endothelial
dysfunction by increasing the production of ROS through
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regulating the activity of nicotinamide adenine dinucleo-
tide phosphate oxidase (NOX) [8]. Several studies have
demonstrated that hypertensive patients and various
animal models of hypertension produce excessive amount
of ROS, and have abnormal levels of antioxidant status,
thereby contributing to the accumulating evidence that
increased vascular oxidative stress could be involved in
the pathogenesis of essential hypertension [9].
ROS are mainly produced by mitochondria. There
are many processes that generate superoxide as a
natural byproduct of mitochondrial metabolism, in-
cluding leakage from electron transport chain (ETC.)
enzymes during oxidative phosphorylation and the
tricarboxylic acid (TCA) cycle. In normal physio-
logical conditions, ROS participate in critical signal-
ing pathways to mediate adaptive responses and regulate
diverse biologies, including cell growth and differentiation
[10]. However, once the balance between production and
detoxification pathways is broken, excess ROS gener-
ation, it will lead to accumulated oxidative damage of
critical macromolecules, such as DNA, RNA, proteins
and lipids [11]. Oxidative stress (OS) contributes to
vascular injury by promoting inflammation, endothe-
lial dysfunction and increased vascular tone, leading
to altered vascular contractility, structural remodeling,
and hypertension as well as other forms of cardiovas-
cular disease [12].
SIRT3 is one of the seven mammalian sirtuins, which are
a conserved family of proteins possessing NAD+-dependent
deacetylase activity. Of the seven sirtuins, SIRT3 is the only
sirtuin analogue whose increased expression was shown to
be associated with longevity of humans [13, 14]. SIRT3 is a
protein of tremendous potential, which can modulate
avariety of cellular processes, including growth arrest,
apoptosis, senescence, and metabolism. SIRT3 resides
primarily in the mitochondria and has been shown to
bind and deacetylate several metabolic and respiratory
enzymes that regulate important mitochondrial func-
tions [15]. Studies in the past few years have shown
that SIRT3 regulate the production and clearance of
ROS through deacetylation of numerous mitochon-
drial enzymes [16–22]. For instance, SIRT3 can re-
duce ROS production via activation of long chain
fatty acyl-CoA dehydrogenase (LCAD), succinate de-
hydrogenase (SDH) and NADH dehydrogenase, as well as
improve ROS clearance through activation manganese
superoxide dismutase (MnSOD) and catalase (CAT). In
the heart, SIRT3 has been found to block development of
cardiac hypertrophy and protect cardiomyocytes from
oxidative stress-mediated cell death [20].
In this study, we investigated the influence of AngII on
the protein expression of SIRT3 in human umbilical vein
endothelial cells (HUVECs) and the role of SIRT3 in
AngII-induced HUVECs dysfunction.
Methods
Cell culture, treatment and transfection
Normal Primary Human umbilical vein endothelial cells
(ATCC® PCS-100-010™) were maintained in endothelial
cell medium (ECM; Sciencell, USA) in humidified incuba-
tor with 5 % CO2 and 95 % air at 37 °C until desired
cell density was reached. Confluent cells cultured up
to 3–7 passages were first starved in 0.5 % fetal bovine
serum ECM for 24 h before exposure to AngII (Sigma;
10−7, 10−6, 10−5 mol/L) for another 24 h.
The SIRT3 siRNA used was synthesized by Shanghai
GenePharma (Shanghai). Negative control siRNA, which
does not target any known gene, was used as a negative
control. Cells were transfected with the siRNAs by the
Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions and examined by western
blot analysis. Cells transfected with SIRT3 siRNA were
then treatment with or without AngII (10−6 mol/L) for 24 h.
Assessment of intracellular ROS levels
Intracellular ROS was detected with 2′,7′-dichlorodihy-
dro-fluorescein diacetate (DCFH-DA; Sigma). Treated
cells were stained with 10 μM DCFH-DA and incubated
in dark at 37 °C for 20 min. The stained cells were
washed 3 times with PBS, and then detected under a
confocal laser scanning microscope (ZEISS LSM 710,
Germany) at an excitation wavelength of 488 nm and an
emission wavelength of 520 nm.
Western blot analysis
Total protein was extracted by total protein extraction kit
(Beyotime, Jiangsu, China). Protein concentration was
measured by BCA protein assay kit (Beyotime, Jiangsu,
China). Each protein sample was loaded onto a 12 % SDS-
PAGE, and then transferred to polyvinylidene difluoride
membranes (Millipore, Billerica, MA). The membrane
was blocked with 5 % milk (in 40 mLTBST) for 2 h before
incubated with primary antibodies against β-actin, SIRT3
and endothelial nitric oxide synthase (eNOS) (all
Cell Signaling Technology) at 4 °C overnight. After
being washed with TBST for 3 times, the membranes
were incubated with secondary anti-rabbit horse-
radish peroxidase-labeled antibody for 2 h and visualized
by enhanced chemiluminescence (Millipore, Billerica, MA).
Real-time PCR
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad,
CA, USA). The first-strand cDNAs were synthesized from
2 μg of total RNAs in 20 ml reaction using Prime
Script RT reagent kit (TaKaRa Biotechnology, Dalian,
China). Quantitative PCR was performed in Eppendorf
Mastercycler ep realplex detection system (Eppendorf,
Hamburg, Germany) by Fast start universal SYBR green
master (Roche, Germany) according to the manufacturer’s
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protocol. The relative mRNA levels were as normalized to
GAPDH and calculated as 2−ΔΔCT.
The primers for PCR are as follow: SIRT3, forward
5′- CCCCAAGCCCTTTTTCACTTT-3′ and reverse
5′-CG ACACTCTCTC AAGCCCA-3′; GAPDH, for-
ward 5′-GAGTCAACGGATTTGGTCG T-3′ and
reverse 5′-AATGAAGGGGTCATTGATGG-3′.
eNOS activity assay
eNOS activity was measured by use of a nitricoxide
synthase assay kit (Beyotime, Jiangsu, China). Treated
cells in 96-well plates were incubated with 100 μL NOS
assay buffer (plus iNOS inhibitor) and 100 μL reaction
buffer (containing 3-amino,4-aminomethayl- 2′,7′-
difluorescein diacetate, DAF-FM DA) per well for
60 min at 37 °C. DAF-FM reacts with NO free radicals,
becoming fluorescent in the presence of NO. Then the
fluorescent identity was determined by microplate reader
(INFINITE M200, Switzerland) analysis at excitation
495 nm and emission 515 nm.
Measurement of NO concentration
The NO levels in the cell culture supernatant were mea-
sured by using nitric oxide assay kit (Beyotime, Jiangsu,
China) in nitrate reductase method. Briefly, standards
were dilute to 0, 1, 2, 5, 10, 20, 40, 60, 100 μM/L with
ECM. 50 μL standards or samples were mixed with
50 μL Griess Reagent I and 50 μL Griess Reagent II at
room temperature, and the absorbance at 540 nm was
measured using a microplate reader (INFINITE M200,
Switzerland). The concentration of NO in the samples
was calculated by using a standard curve of sodium
nitrite.
Statistical analysis
The data are expressed as mean ± SEM The difference
between groups was analyzed by a one-way analysis of
variance. P < 0.05 was considered statistically significant.
Results
Dose-dependent effects of AngII on SIRT3 expression of
HUVECS
Treatment with 0, 10−7, 10−6, 10−5 mol/L AngII for 24 h
resulted in a significant increase of SIRT3 protein
expression in HUVECS, with the peak at 10−6 mol/L
(Fig. 1a and b). The mRNA expression levels of SIRT3
were also increased significantly (Fig. 1c). The dose of
10−6 mol/L was selected for the treatment condition
in subsequent experiments.
Screening of SIRT3 siRNA sequences
Inhibition efficiency of SIRT3 siRNA sequences were
examined by western blot analysis. The inhibition effi-
ciency of SIRT3-homo-340 is the highest (Fig. 2a and b).
SIRT3 siRNA sequences SIRT3-homo-340 was screened
for subsequent experiments.
Fig. 1 Dose-dependent effects of AngII on SIRT3 expression. Cells were stimulated by AngII of 0, 10−7,10−6,10−5 mol/L for 24 h, SIRT3 protein
expression were determined by western blot in each group (a) and Quantification of SIRT3 in each group, β-actin as a reference (b).
SIRT3 mRNA expression were determined by RT-PCR (c). Data are the mean ± SEM from three separate experiments. *P < 0.05 vs. control,
#P < 0.05 vs.10−6 mol/L group
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Knockdown of SIRT3 worsen the AngII-induced effects on
HUVECS
AngII (10−6 mol/L) induced an obvious pathological
phenotype of HUVECS, as shown by a reduced eNOS
activity (0.78, *P < 0.05 versus NC, Fig. 3e) and reduced
NO concentration (0.70,*P < 0.05 versus NC, Fig. 3f ),
however, eNOS expression increased in response to
AngIIstimuli (Fig. 3b and d). When SIRT3 was knocked
down using siRNA, the activity of eNOS in SIRT3
siRNA +AngII group decreased more significantly than
that in AngII group (0.52 in SIRT3 siRNA +AngII
group, 0.78 in AngII group, #P < 0.05, Fig. 3e). The
concentration of NO further decreased when pretreated
with SIRT3 siRNA (0.43 in SIRT3 siRNA + AngII group,
0.70 in AngII group, #P < 0.05, Fig. 3f ). In addition,
treatment with SIRT3 siRNA reduced eNOS expression
under conditions with or without AngII (Fig. 3b and d).
The effect of SIRT3 on ROS level in HUVECs treated with
AngII
To confirm the role of SIRT3 in AngII-induced oxidative
stress injury in HUVECs, cells pretreated with negative
control siRNA or SIRT3 siRNA were exposed to AngII
for 24 h. SIRT3 significantly increased ROS level of cells
with or without intervention of AngII (Fig. 4c).
Fig. 2 Screening of SIRT3 siRNA sequences. Cells were transfected by
SIRT3 siRNA of different sequences. SIRT3 expression were determined
by western blot in each group (a) and Quantification of SIRT3 in each
group, β-actin as a reference (b). Data are the mean ± SEM from three
separate experiments. *P < 0.05 vs. Negative Control (NC)
Fig. 3 Knockdown of SIRT3 worsen the AngII-induced effects on HUVECS. Cells transfected with negative control siRNA or SIRT3 siRNA
were then treatment with AngII for 24 h. SIRT3 expression were determined by western blot in each group (a) and Quantification of
SIRT3 in each group, β-actin as a reference (c). eNOS expression were determined by western blot in each group (b) and Quantification
of eNOS in each group, β-actin as a reference (d). eNOS activity in each group (e), NO concentration in each group (f). Data are the
mean ± SEM from three separate experiments. *P < 0.05 vs. Negative Control (NC), #P < 0.05 vs. AngII group
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Discussion
In this study, we found that AngII could upregulate SIRT3
expression in HUVECs distinctly. SIRT3 siRNA could
worsen AngII induced endothelial dysfunction via increase
generation of ROS.
Endothelial dysfunction has been implicated in the
pathophysiology of atherosclerosis, hypertension, and heart
failure. It could be defined as impairment characterized of
reduced vasodilation, a proinflammatory state, and pro-
thrombotic setting. Oxidatative stress has been confirmed
as one of the major mechanisms responsible for the forma-
tion and development of endothelial dysfunction [6]. There
is considerable evidence supporting the view that oxidative
stress is involved in the pathophysiology of cardiovascular
diseases. Oxidative stress can result not only from increased
ROS production, but also from decreased ROS scavenging
ability. Hypertension is reported to be associated with de-
creased antioxidant systems as well as enhanced production
of ROS [23]. NOX is the primary biochemical source of
ROS in the vasculature, particularly of superoxide. The vas-
culature is rich sources of NOX-derived ROS, which under
pathological conditions play an important role in vascular
damage [24]. AngII is the most studied stimulus of NOX
activation. Previous studies indicated that in rats and mice
made hypertensive by AngII infusion, expression of NOX
subunits, oxidase activity, and generation of ROS are all
increased [25]. Likely the most well-known function of
NOX derived superoxide is inactivation of NO to form
peroxynitrite, leading to impaired endothelium-dependent
vasodilation and uncoupling of eNOS to produce
additional superoxide [26]. In the vasculature, NOX
activation has been strongly associated with hypertension.
The primary function of eNOS is NO production. NO is
known as a key paracrine regulator of vascular tone [27].
Physiologically, NO inhibits leukocyte-endothelial cell
adhesion, VSMC proliferation and migration, and plate-
let aggregation to maintain the health of the vascular
endothelium. The reduction in bioavailability of NO in
the vasculature decreases vasodilatory capacity and con-
tributes to endothelial dysfunction. Our results confirmed
these findings that AngII treatment could increase gener-
ation of ROS and decrease eNOS activity and total level of
NO, while eNOS protein expression was up-regulated.
We consider that AngII induced up-regulated of eNOS
protein expression may be a compensatory reflection.
Mitochondria are the primary sources of ROS, as there
are many processes that generate superoxide as a natural
byproduct of mitochondrial metabolism, such as leakage
from ETC. enzymes during oxidative phosphorylation
and the TCA cycle. SIRT3 resides primarily in the mito-
chondria and has been shown to regulate production
and clearance of ROS via deacetylation of numerous
mitochondrial enzymes. Recently researches have reported
that SIRT3 prevented cardiac hypertrophic response by
scavenging ROS through activation of Foxo3a and upregu-
lation of MnSOD and CAT [20]. In our study, SIRT3-
siRNA increased HUVECs ROS under the stimulation of
AngII. This is consistent with a previous paper showing
that SIRT3 is required to reduce cellular ROS in particular
under the conditions of stress [28].
Fig. 4 The effect of SIRT3 on ROS level in HUVECs treated with AngIIThe effect of SIRT3 on ROS level in HUVECs treated with AngII. Cells pretreated
with negative control siRNA or SIRT3 siRNA were exposed to AngII for 24 h. SIRT3 expression were determined by western blot in each group (a) and
Quantification of SIRT3 in each group, β-actin as a reference (b). ROS levels in each group (c). Original magnification × 200. Data are the mean ± SEM
from three separate experiments. *P < 0.05 vs. Negative Control (NC), #P < 0.05 vs. AngII group
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NAD+ is a substrate for the class III NAD+-dependent
deacetylase Sirtuins, and a powerful activator of the
Sirtuin activity. The enzymatic activity SIRT3 is sensitive
to NAD+/NADH ratio [29]. It has been proved that
NADH accumulation and decreased NAD+/NADH ratio
caused by complex I deficiency inhibits SIRT3 activity
[30]. The mechanism of SIRT3 expression increase
induced by AngII can be presumed that a change in the
cellular NAD+/NADH ratio, in part, contribute to increased
levels of SIRT3, based on studies with other sirtuins, It has
been reported that decreased NADH levels following
calorie restriction, which increased the NAD+/NADH ratio,
elevated levels of yeast Sir2 [31]. In addition, research
shows that SIRT3 expression is regulated in response to
mitochondrial oxidative stress in primary hippocampal cell
[32]. Therefore, we speculate that the upregulation of
SIRT3 expression induced by AngII could be due to the
increase of NAD+/NADH ratio and accumulation of ROS
through activation of NOX. We considered that the upreg-
ulation of SIRT3 induced by AngII was a protective effect
as compensative response. In our study, we use SIRT3
siRNA to knock down SIRT3 expression in HUVECs, and
knock down of SIRT3 worsen AngII-induced pathological
phenotype of HUVECS as shown by reduced eNOS activity,
NO concentration and eNOS expression.
Conclusion
These data suggest that SIRT3 plays a protective role in
AngII-induced HUVECs dysfunction via regulation of
ROS generation. Our study provides evidences for
further researches on the role of SIRT3 in cardiovascular
diseases.
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